Loading market dashboard
Pangea Wellness Inc.
PNGAFConsumer DefensiveOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that, further to its news release dated October 15, 2025, it has extended its existing agreement with Emerging Markets Consulting, LLC ("EMC") for the continued provision of investor relations and communication services by EMC for an additional six month term. Emerging Markets Consulting, LLC Based in Orlando, Florida, EMC brings multiple decades of combined experience in the investor relations industry.
Highlights Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner Compounding activities under the agreement expected to commence on Monday, June 1, 2026 All peptides under the agreement to be 100% compounded in the United States Designed to support prescription-based peptide preparation and fulfillment, including BPC-157 Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states Strengthens the Company's U.S. supply chain and regulatory footprint Comes amid recent U.S. regulatory developments advancing clarity around peptide substances, including the FDA's referral of multiple peptides to the Pharmacy Compounding Advisory Committee (PCAC) for evidence-based evaluation Vancouver, British Columbia--(Newsfile Corp. - June 2, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has entered into a compounding agreement (the "Compounding Agreement") with a U.S.-based 503A sterile compounding pharmacy (the "Compounding Partner") for the future prescription-based preparation and fulfillment of the Company's peptide products, including BPC-157. Under the Compounding Agreement, the Compounding Partner will provide the Company with access to large-scale pharmaceutical compounding infrastructure with the capacity to fulfill up to approximately 25,000 prescriptions per day across all U.S. states.
Highlights Only peptide company exhibiting at BEYOND 2026, Dave Asprey's flagship biohacking, longevity, and consciousness conference Three immersive days in Austin, Texas — May 27-29, 2026 5,000+ attendees, 100+ speakers, 150+ exhibiting partners, and 30 experiential "hacktivations" Dedicated booth showcasing the Company's peptide product line, including the needle-free BPC-157 transdermal patch Event comes ahead of the previously announced feature of CSO Justin Kirkland on The Human Upgrade with Dave Asprey, airing in June 2026 Vancouver, British Columbia--(Newsfile Corp. - May 28, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces its participation in BEYOND, the biohacking, longevity, and consciousness conference founded and led by Dave Asprey, taking place May 27-29, 2026 in Austin, Texas. The Company will be the only peptide company exhibiting on the show floor and will operate a dedicated booth showcasing its peptide product line, including the needle-free BPC-157 transdermal patch.
Highlights Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The order is intended to support the Patch's planned commercial release.
Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and Board Director Laura Sanko Highlights Exclusive access to MMA.INC's global combat sports ecosystem1 of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years2) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko 50/50 net revenue share in Year 1, transitioning to 75/25 in favor of Precision thereafter, with no upfront capital investment All Precision products are U.S. manufactured and third party tested, positioning the Company as a compliance first operator New high margin commercialization vertical into a large and engaged athletic community Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "Precision"), a publicly traded wellness company building a platform for high quality peptide formulations, today provides additional detail on its previously announced Exclusive Strategic Marketing Agreement (the "Agreement") with Mixed Martial Arts Group Limited ("MMA"), and outlines the strategic significance of the partnership for the Company's commercialization roadmap. A Differentiated Channel Into the Global Combat Sports Community Under the Agreement, Precision has secured exclusive marketing rights across MMA.INC's digitally connected combat sports ecosystem, which the Company believes represents a highly engaged, performance driven and recovery-focused consumer demographic.
Highlights The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products Results support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launch Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹ Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products² Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two PhD scientists Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today reports initial third-party test results for its needle free BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The Results Independent analytical laboratory Miraxis Labs, based in San Diego, California, has tested the patch and confirmed: 95.5% chromatographic purity 2.02 mg of BPC-157 per patch (quantified potency) Both results were measured using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD).
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that Justin Kirkland, Co-Founder and Chief Scientific Officer of the Company's wholly-owned subsidiary Amino Innovations, will be featured as a guest on an upcoming episode of The Human Upgrade with Dave Asprey. The Human Upgrade, hosted by Dave Asprey, is a platform in the biohacking, longevity, and human performance space, with a global audience built over more than a decade of conversations on health optimization, advanced wellness, and emerging science.
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or
First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time. The BPC-157 patch is currently in active testing, with results anticipated in the near term.
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") a publicly traded wellness company focused on advanced peptide formulations and delivery systems, announces the receipt of approximately C$1.3 million from the exercise of outstanding warrants. The proceeds strengthen the Company's balance sheet and will be used to support the continued development and expansion of its Amino Innovations platform, including product rollout, delivery technology advancement, and distribution growth across North America.
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, announces the grant of restricted share units (the "RSUs") and incentive stock options (the "Options") pursuant to the Company's omnibus share incentive plan, as well as the issuance of common shares to settle outstanding indebtedness owed to a creditor of the Company. RSU Grant The Company has granted a total of 600,000 RSUs to certain director of the Company.
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it has entered into a strategic product marketing agreement with Raw Creation, a UK-headquartered creative agency ("Raw Creation"), to provide certain social media management, creative content, editorial, paid advertising and related marketing services to the Company (the "Agreement"). Pursuant to the Agreement, Raw Creation shall provide the following services: (i) social media management across various social media platforms; (ii) creative and video production; (iii) editorial and press services, including blog articles, press releases drafted with public-markets compliance, landing pages and social copy; and (iv) paid advertising management (collectively, the "Services").
Vancouver, British Columbia--(Newsfile Corp. - April 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a company focused on the next-generation of peptide-based products and delivery systems, commends the U.S. Food and Drug Administration (FDA) for its recent actions to advance regulatory clarity surrounding peptide substances. The FDA's decision to remove several peptides from Category 2 of bulk drug substances and refer them to further evaluation by the Pharmacy Compounding Advisory Committee (PCAC) marks a meaningful step toward establishing a more transparent and science-driven regulatory framework.
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it has entered into agreements with i) Think Ink Marketing Data and Email Services ("Think Ink") and ii) Ouimet Consulting Inc. ("Ouimet") to provide certain investor relations services to the Company. Think Ink The Company has entered into a public relations services agreement with Think Ink (the "Think Ink Agreement").
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a
Vancouver, BC – March 13, 2026 – TheNewswire - Pangea Wellness Inc. (“Pangea” or the “Company”) (CSE: PNGA) (OTC: PNGAF) announces that further to the Company's news release dated March 6, 2026, the effective date of the name change from “Pangea Wellness Inc.” to The Precision Peptide Company Inc.” will be March 18, 2026. The Company's common shares will begin trading on the CSE on March 18, 2026 under the new name and trading symbol “BPC”. The new CUSIP will be 74031F104 and the new ISIN number will be CA74031F1045. The share capital of the Company remains unchanged.
